Accounting for Hypoglycemia Treatments in Continuous Glucose Metrics

Elliott C Pryor1, Anas El Fathi1, Marc D Breton1

  • 1Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.

Insights

Continuous glucose monitoring (CGM) data can be improved by accounting for hypoglycemia treatments (HTs). New methods accurately quantify avoided hypoglycemia, enhancing diabetes management and treatment adaptation for better blood glucose control.

Area of Science:

  • Biomedical Engineering
  • Data Science in Healthcare
  • Endocrinology

Background:

  • Continuous glucose monitoring (CGM) provides valuable diabetes data but omits behavioral factors like hypoglycemia treatments (HTs).
  • Hypoglycemia treatments mask actual glucose exposure, potentially leading to management errors.
  • Accurate assessment of hypoglycemia requires integrating behavioral data with CGM metrics.

Purpose of the Study:

  • To develop a method for incorporating HTs into CGM-based metrics.
  • To standardize the quantification of hypoglycemia exposure considering treatment proactiveness and severity.
  • To introduce an HT detector for identifying undocumented HTs in CGM data.

Main Methods:

  • Proposed a novel method to integrate HTs into CGM metrics for standardized hypoglycemia quantification.
  • Developed an HT detector to identify treatment instances within CGM data.
  • Applied HT-modified hypoglycemia metrics to a run-to-run treatment adaptation system.

Main Results:

  • Reconstructed avoided hypoglycemia exposure with high fidelity (R² = .94) using in-silico data.
  • Achieved an F1 score of 0.72 for the HT detector on clinical data.
  • Reduced average daily HTs from 3.3 to 1.6 in a run-to-run system while maintaining 84% time in range.

Conclusions:

  • The new metric integrates HT behaviors into CGM analysis for behavior-sensitive hypoglycemia assessment.
  • This approach enhances Type 1 Diabetes (T1D) management by providing more robust treatment insights.
  • HT variability can be seamlessly incorporated into existing CGM methods for improved diabetes care.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
SBAR II: Application of SBAR01:14

SBAR II: Application of SBAR

SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
128